

Kurt Jarnagin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11300767/publications.pdf>

Version: 2024-02-01

38
papers

3,925
citations

218677

26
h-index

330143

37
g-index

39
all docs

39
docs citations

39
times ranked

3155
citing authors

#	ARTICLE	IF	CITATIONS
1	Macrophilicidal Benzimidazole-Benzoxaborole Hybrids as an Approach to the Treatment of River Blindness: Part 1. Amide Linked Analogs. <i>ACS Infectious Diseases</i> , 2020, 6, 173-179.	3.8	11
2	Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005680.	3.0	36
3	Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 358, 413-422.	2.5	55
4	Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis. <i>Journal of Drugs in Dermatology</i> , 2016, 15, 390-6.	0.8	52
5	Discovery and structure-activity relationships of 6-(benzoylamino)benzoxaboroles as orally active anti-inflammatory agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5870-5873.	2.2	21
6	Structure-activity relationships of 6-(aminomethylphenoxy)-benzoxaborole derivatives as anti-inflammatory agent. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1680-1683.	2.2	25
7	Inhibition of Toll-Like Receptor-Mediated Inflammation In Vitro and In Vivo by a Novel Benzoxaborole. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 436-446.	2.5	12
8	Linking Phenotype to Kinase: Identification of a Novel Benzoxaborole Hinge-Binding Motif for Kinase Inhibition and Development of High-Potency Rho Kinase Inhibitors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 347, 615-625.	2.5	47
9	Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. <i>FEBS Letters</i> , 2012, 586, 3410-3414.	2.8	88
10	Early rapid identification of in vivo rat metabolites of AN6414, a novel boron-containing PDE4 inhibitor by QTRAP LC/MS/MS to support drug discovery. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 70, 344-353.	2.8	24
11	Discovery of Novel Orally Bioavailable Oxaborole 6-Carboxamides That Demonstrate Cure in a Murine Model of Late-Stage Central Nervous System African Trypanosomiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4379-4388.	3.2	95
12	The liver pharmacological and xenobiotic gene response repertoire. <i>Molecular Systems Biology</i> , 2008, 4, 175.	7.2	71
13	NSAID-Induced Acute Phase Response is Due to Increased Intestinal Permeability and Characterized by Early and Consistent Alterations in Hepatic Gene Expression. <i>Toxicologic Pathology</i> , 2006, 34, 168-179.	1.8	51
14	Classification of a large microarray data set: Algorithm comparison and analysis of drug signatures. <i>Genome Research</i> , 2005, 15, 724-736.	5.5	104
15	A Gene Expression Signature that Predicts the Future Onset of Drug-Induced Renal Tubular Toxicity. <i>Toxicologic Pathology</i> , 2005, 33, 675-683.	1.8	112
16	Use of a mixed tissue RNA design for performance assessments on multiple microarray formats. <i>Nucleic Acids Research</i> , 2005, 33, e187-e187.	14.5	30
17	Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. <i>Journal of Biotechnology</i> , 2005, 119, 219-244.	3.8	282
18	Differential Distribution of Bradykinin B ₂ Receptors in the Rat and Human Cardiovascular System. <i>Hypertension</i> , 2001, 37, 110-120.	2.7	49

#	ARTICLE	IF	CITATIONS
19	Structure-based design of six novel classes of nonpeptide antagonists of the bradykinin B2 receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2000, 10, 2421-2425.	2.2	11
20	Identification of the Binding Site for a Novel Class of CCR2b Chemokine Receptor Antagonists. <i>Journal of Biological Chemistry</i> , 2000, 275, 25562-25571.	3.4	232
21	Identification of Surface Residues of the Monocyte Chemotactic Protein 1 That Affect Signaling through the Receptor CCR2. <i>Biochemistry</i> , 1999, 38, 16167-16177.	2.5	103
22	Identification of Residues in the Monocyte Chemotactic Protein-1 That Contact the MCP-1 Receptor, CCR2. <i>Biochemistry</i> , 1999, 38, 13013-13025.	2.5	141
23	Purification and physical characterization of cloned human cAMP phosphodiesterases PDE-4D and-4C. <i>Cell Biochemistry and Biophysics</i> , 1998, 28, 187-217.	1.8	6
24	Comparison of Recombinant Human PDE4 Isoforms. <i>Cellular Signalling</i> , 1998, 10, 427-440.	3.6	52
25	Monomeric Monocyte Chemoattractant Protein-1 (MCP-1) Binds and Activates the MCP-1 Receptor CCR2B. <i>Journal of Biological Chemistry</i> , 1998, 273, 33157-33165.	3.4	183
26	Multiple splice variants of phosphodiesterase PDE4C cloned from human lung and testis. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1997, 1353, 287-297.	2.4	38
27	Nonpeptide bradykinin antagonist analogs based on a model of a Sterling-Winthrop nonpeptide bradykinin antagonist overlapped with cyclic hexapeptide bradykinin antagonist peptides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1997, 7, 1921-1926.	2.2	6
28	Na ⁺ Ions Binding to the Bradykinin B2Receptor Suppress Agonist-Independent Receptor Activation. <i>Biochemistry</i> , 1996, 35, 13368-13377.	2.5	42
29	Mutations in the B2 Bradykinin Receptor Reveal a Different Pattern of Contacts for Peptidic Agonists and Peptidic Antagonists. <i>Journal of Biological Chemistry</i> , 1996, 271, 28277-28286.	3.4	62
30	The N-terminal Amino Group of [Tyr8]Bradykinin Is Bound Adjacent to Analogous Amino Acids of the Human and Rat B2 Receptor. <i>Journal of Biological Chemistry</i> , 1996, 271, 27382-27387.	3.4	27
31	Extracellular Domains of the Bradykinin B2 Receptor Involved in Ligand Binding and Agonist Sensing Defined by Anti-peptide Antibodies. <i>Journal of Biological Chemistry</i> , 1996, 271, 1748-1755.	3.4	83
32	Cyclic hexapeptide antagonists of the bradykinin B2 receptor: Receptor binding and solution backbone conformation. <i>International Journal of Peptide Research and Therapeutics</i> , 1995, 1, 229-234.	0.1	5
33	Cloning and functional expression of the cDNA encoding rat lanosterol 14- α demethylase. <i>Gene</i> , 1995, 161, 243-248.	2.2	31
34	The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family. <i>Gene</i> , 1993, 129, 239-247.	2.2	78
35	Fed-batch culture of insect cells: a method to increase the yield of recombinant human nerve growth factor (rhNGF) in the baculovirus expression system. <i>Journal of Biotechnology</i> , 1993, 31, 205-217.	3.8	72
36	Cloning of a B2 Bradykinin Receptor: Examination of the Bradykinin Binding Site by Site Directed Mutagenesis. , 1992, 38 (Pt 1), 487-496.		6

#	ARTICLE	IF	CITATIONS
37	Physicochemical Characterization of Recombinant Human Nerve Growth Factor Produced in Insect Cells with a Baculovirus Vector. <i>Journal of Neurochemistry</i> , 1991, 57, 1052-1061.	3.9	19
38	The human insulin receptor cDNA: The structural basis for hormone-activated transmembrane signalling. <i>Cell</i> , 1985, 40, 747-758.	28.9	1,563